Allison W Kurian

List of Publications by Year in Descending Order

280 papers	8,586 citations	53 h-index	87 g-index
318 ext. papers	11,095 ext. citations	5.5 avg, IF	6.11 L-index

#	Paper	IF	Citations
280	Rare germline copy number variants (CNVs) and breast cancer risk.. *Communications Biology*, **2022**, 5, 65	6.7	0
279	Common variants in breast cancer risk loci predispose to distinct tumor subtypes.. *Breast Cancer Research*, **2022**, 24, 2	8.3	3
278	Breast Cancer Screening Strategies for Women With ATM, CHEK2, and PALB2 Pathogenic Variants: A Comparative Modeling Analysis.. *JAMA Oncology*, **2022**,	13.4	5
277	Abstract P2-11-21: Integration of an ancestrally unbiased polygenic risk score with the Tyrer-Cuzick breast cancer risk model. *Cancer Research*, **2022**, 82, P2-11-21-P2-11-21	10.1	
276	Trends in Annual Surveillance Mammography Participation Among Breast Cancer Survivors From 2004 to 2016.. *Journal of the National Comprehensive Cancer Network: JNCCN*, **2022**, 20, 379-386.e9	7.3	
275	Genome-wide and transcriptome-wide association studies of mammographic density phenotypes reveal novel loci.. *Breast Cancer Research*, **2022**, 24, 27	8.3	1
274	Relevance of the MHC region for breast cancer susceptibility in Asians.. *Breast Cancer*, **2022**, 1	3.4	
273	Personalised Risk Prediction in Hereditary Breast and Ovarian Cancer: A Protocol for a Multi-Centre Randomised Controlled Trial. *Cancers*, **2022**, 14, 2716	6.6	1
272	Reply to Ritzwoller et al. *JCO Clinical Cancer Informatics*, **2021**, 5, 1026-1027	5.2	
271	Germline variants and breast cancer survival in patients with distant metastases at primary breast cancer diagnosis. *Scientific Reports*, **2021**, 11, 19787	4.9	0
270	Multiple imputation with missing data indicators. *Statistical Methods in Medical Research*, **2021**, 30, 2685-2700	2.7	2
269	Germline Pathogenic Variants in Cancer Predisposition Genes Among Women With Invasive Lobular Carcinoma of the Breast. *Journal of Clinical Oncology*, **2021**, 39, 3918-3926	2.2	6
268	Racial/Ethnic Disparities in Survival after Breast Cancer Diagnosis by Estrogen and Progesterone Receptor Status: A Pooled Analysis. *Cancer Epidemiology Biomarkers and Prevention*, **2021**, 30, 351-363	4	2
267	Patterns of social media use and associations with psychosocial outcomes among breast and gynecologic cancer survivors. *Journal of Cancer Survivorship*, **2021**, 15, 677-684	5.1	1
266	Benchmark Method for Cost Computations Across Health Care Systems: Cost of Care per Patient per Day in Breast Cancer Care. *JCO Oncology Practice*, **2021**, 17, e1403-e1412	2.3	1
265	Limited English Proficiency and Disparities in Health Care Engagement Among Patients With Breast Cancer. *JCO Oncology Practice*, **2021**, 17, e1837-e1845	2.3	3
264	Development and Use of Natural Language Processing for Identification of Distant Cancer Recurrence and Sites of Distant Recurrence Using Unstructured Electronic Health Record Data. *JCO Clinical Cancer Informatics*, **2021**, 5, 469-478	5.2	2

263	Treatment and Monitoring Variability in US Metastatic Breast Cancer Care. *JCO Clinical Cancer Informatics*, **2021**, 5, 600-614	5.2	1
262	Time Trends in Receipt of Germline Genetic Testing and Results for Women Diagnosed With Breast Cancer or Ovarian Cancer, 2012-2019. *Journal of Clinical Oncology*, **2021**, 39, 1631-1640	2.2	15
261	Multicancer hereditary syndrome testing: Genetic counselors perspectives.. *Journal of Clinical Oncology*, **2021**, 39, 10594-10594	2.2	
260	Cancer-specific mortality associated with germline genetic testing results among women with breast cancer or ovarian cancer treated with chemotherapy.. *Journal of Clinical Oncology*, **2021**, 39, 10517-10517	2.2	
259	Twenty-one-gene recurrence score (RS) in germline (g)CHEK2 mutation-associated versus sporadic breast cancers (BC): A multi-site case-control study.. *Journal of Clinical Oncology*, **2021**, 39, 10531-10531	2.2	
258	Impact of disruptions in breast cancer control due to the COVID-19 pandemic on breast cancer mortality in the United States: Estimates from collaborative simulation modeling.. *Journal of Clinical Oncology*, **2021**, 39, 6562-6562	2.2	
257	Breast cancer screening for carriers of ATM, CHEK2, and PALB2 pathogenic variants: A comparative modeling analysis.. *Journal of Clinical Oncology*, **2021**, 39, 10500-10500	2.2	
256	Weakly supervised temporal model for prediction of breast cancer distant recurrence. *Scientific Reports*, **2021**, 11, 9461	4.9	2
255	A simulation model-based clinical decision tool to guide personalized treatment based on individual characteristics: Does 21-gene recurrence score assay testing change decisions?. *Journal of Clinical Oncology*, **2021**, 39, e12507-e12507	2.2	
254	Comprehensive Breast Cancer Risk Assessment for and Pathogenic Variant Carriers Incorporating a Polygenic Risk Score and the Tyrer-Cuzick Model. *JCO Precision Oncology*, **2021**, 5,	3.6	2
253	Receipt of guideline-concordant care among young adult women with breast cancer. *Cancer*, **2021**, 127, 3325-3333	6.4	0
252	Tobacco Smoking and Risk of Second Primary Lung Cancer. *Journal of Thoracic Oncology*, **2021**, 16, 968-979	13.9	11
251	Functional annotation of the 2q35 breast cancer risk locus implicates a structural variant in influencing activity of a long-range enhancer element. *American Journal of Human Genetics*, **2021**, 108, 1190-1203	11	1
250	Influence of payer coverage and out-of-pocket costs on ordering of NGS panel tests for hereditary cancer in diverse settings. *Journal of Genetic Counseling*, **2021**,	2.5	2
249	Combined Associations of a Polygenic Risk Score and Classical Risk Factors With Breast Cancer Risk. *Journal of the National Cancer Institute*, **2021**, 113, 329-337	9.7	14
248	Predicted Chemotherapy Benefit for Breast Cancer Patients With Germline Pathogenic Variants in Cancer Susceptibility Genes. *JNCI Cancer Spectrum*, **2021**, 5, pkaa083	4.6	0
247	Comparing 5-Year and Lifetime Risks of Breast Cancer using the Prospective Family Study Cohort. *Journal of the National Cancer Institute*, **2021**, 113, 785-791	9.7	5
246	CYP3A7*1C allele: linking premenopausal oestrone and progesterone levels with risk of hormone receptor-positive breast cancers. *British Journal of Cancer*, **2021**, 124, 842-854	8.7	2

245	Impact of the COVID-19 Pandemic on Breast Cancer Mortality in the US: Estimates From Collaborative Simulation Modeling. *Journal of the National Cancer Institute*, **2021**, 113, 1484-1494	9.7	22
244	A case-only study to identify genetic modifiers of breast cancer risk for BRCA1/BRCA2 mutation carriers. *Nature Communications*, **2021**, 12, 1078	17.4	4
243	A Population-Based Study of Genes Previously Implicated in Breast Cancer. *New England Journal of Medicine*, **2021**, 384, 440-451	59.2	115
242	Association of Risk-Reducing Salpingo-Oophorectomy With Breast Cancer Risk in Women With BRCA1 and BRCA2 Pathogenic Variants. *JAMA Oncology*, **2021**, 7, 585-592	13.4	5
241	Performance of the IBIS/Tyrer-Cuzick model of breast cancer risk by race and ethnicity in the Women's Health Initiative. *Cancer*, **2021**, 127, 3742-3750	6.4	2
240	Association of germline genetic variants with breast cancer-specific survival in patient subgroups defined by clinic-pathological variables related to tumor biology and type of systemic treatment. *Breast Cancer Research*, **2021**, 23, 86	8.3	1
239	Mendelian randomisation study of smoking exposure in relation to breast cancer risk. *British Journal of Cancer*, **2021**, 125, 1135-1145	8.7	0
238	Genetic insights into biological mechanisms governing human ovarian ageing. *Nature*, **2021**, 596, 393-397	50.4	28
237	Development of a Mobile Health App (TOGETHERCare) to Reduce Cancer Care Partner Burden: Product Design Study. *JMIR Formative Research*, **2021**, 5, e22608	2.5	0
236	Development and Validation of a Simulation Model-Based Clinical Decision Tool: Identifying Patients Where 21-Gene Recurrence Score Testing May Change Decisions. *Journal of Clinical Oncology*, **2021**, 39, 2893-2902	2.2	3
235	The Impact of COVID-19 on Patients With Cancer: A National Study of Patient Experiences. *American Journal of Clinical Oncology: Cancer Clinical Trials*, **2021**, 44, 580-587	2.7	6
234	Impact of Low-Dose Computed Tomography Screening for Primary Lung Cancer on Subsequent Risk of Brain Metastasis. *Journal of Thoracic Oncology*, **2021**, 16, 1479-1489	8.9	2
233	Multicancer hereditary syndrome testing: Genetic counselors perspectives.. *Journal of Clinical Oncology*, **2021**, 39, 106-106	2.2	
232	Germline Pathogenic Variants in the Ataxia Telangiectasia Mutated () Gene are Associated with High and Moderate Risks for Multiple Cancers. *Cancer Prevention Research*, **2021**, 14, 433-440	3.2	16
231	Integrating Clinical and Polygenic Factors to Predict Breast Cancer Risk in Women Undergoing Genetic Testing. *JCO Precision Oncology*, **2021**, 5,	3.6	8
230	Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. *Journal of the National Comprehensive Cancer Network: JNCCN*, **2021**, 19, 77-102	7.3	131
229	Prevalence of Lynch syndrome in women with mismatch repair-deficient ovarian cancer. *Cancer Medicine*, **2021**, 10, 1012-1017	4.8	5
228	Psychosocial outcomes following germline multigene panel testing in an ethnically and economically diverse cohort of patients. *Cancer*, **2021**, 127, 1275-1285	6.4	7

227	Polygenic risk scores for prediction of breast cancer risk in Asian populations.. *Genetics in Medicine*, **2021**,	8.1	2
226	Recreational Physical Activity and Outcomes After Breast Cancer in Women at High Familial Risk.. *JNCI Cancer Spectrum*, **2021**, 5, pkab090	4.6	0
225	Simulation modeling of breast cancer endocrine therapy duration by patient and tumor characteristics.. *Cancer Medicine*, **2021**,	4.8	1
224	Yield and Utility of Germline Testing Following Tumor Sequencing in Patients With Cancer. *JAMA Network Open*, **2020**, 3, e2019452	10.4	25
223	Projected Reductions in Absolute Cancer-Related Deaths from Diagnosing Cancers Before Metastasis, 2006-2015. *Cancer Epidemiology Biomarkers and Prevention*, **2020**, 29, 895-902	4	11
222	Germline HOXB13 mutations p.G84E and p.R217C do not confer an increased breast cancer risk. *Scientific Reports*, **2020**, 10, 9688	4.9	2
221	Development and Validation of a Clinical Polygenic Risk Score to Predict Breast Cancer Risk. *JCO Precision Oncology*, **2020**, 4,	3.6	16
220	Hospital Characteristics and Breast Cancer Survival in the California Breast Cancer Survivorship Consortium. *JCO Oncology Practice*, **2020**, 16, e517-e528	2.3	1
219	Prevalence of Pathogenic Variants in Cancer Susceptibility Genes Among Women With Postmenopausal Breast Cancer. *JAMA - Journal of the American Medical Association*, **2020**, 323, 995-997	27.4	14
218	Identification of novel breast cancer susceptibility loci in meta-analyses conducted among Asian and European descendants. *Nature Communications*, **2020**, 11, 1217	17.4	16
217	Characterization of the Cancer Spectrum in Men With Germline BRCA1 and BRCA2 Pathogenic Variants: Results From the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA). *JAMA Oncology*, **2020**, 6, 1218-1230	13.4	25
216	Health Disparities in Germline Genetic Testing for Cancer Susceptibility. *Current Breast Cancer Reports*, **2020**, 12, 51-58	0.8	2
215	Association of Germline Genetic Testing Results With Locoregional and Systemic Therapy in Patients With Breast Cancer. *JAMA Oncology*, **2020**, 6, e196400	13.4	11
214	Insights From a Temporal Assessment of Increases in US Private Payer Coverage of Tumor Sequencing From 2015 to 2019. *Value in Health*, **2020**, 23, 551-558	3.3	6
213	A case of a trans-masculine patient receiving testosterone with a history of estrogen receptor-positive breast cancer. *Breast Journal*, **2020**, 26, 1888-1889	1.2	0
212	Performance of the IBIS/Tyrer-Cuzick (TC) Model by race/ethnicity in the Women's Health Initiative.. *Journal of Clinical Oncology*, **2020**, 38, 1503-1503	2.2	2
211	Reply to Residual confounding threatens the validity of observational studies on breast cancer local therapy. *Cancer*, **2020**, 126, 2317-2318	6.4	
210	Trends in germline genetic testing and results into survivorship for women diagnosed with breast cancer or ovarian cancer, 2013 to 2017.. *Journal of Clinical Oncology*, **2020**, 38, 273-273	2.2	

209	NCCN Guidelines Insights: Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 1.2020. *Journal of the National Comprehensive Cancer Network: JNCCN*, **2020**, 18, 380-391	7.3	171
208	Linking insurance claims across time to characterize treatment, monitoring, and end-of-life care in metastatic breast cancer.. *Journal of Clinical Oncology*, **2020**, 38, 7063-7063	2.2	
207	Comprehensive breast cancer (BC) risk assessment for CHEK2 carriers incorporating a polygenic risk score (PRS) and the Tyrer-Cuzick (TC) model.. *Journal of Clinical Oncology*, **2020**, 38, 1504-1504	2.2	
206	Clinicopathologic features of invasive breast cancer (BC) diagnosed in carriers of germline PALB2, CHEK2 and ATM pathogenic variants.. *Journal of Clinical Oncology*, **2020**, 38, 1549-1549	2.2	
205	Real-world outcomes of patients with metastatic breast cancer (BC) treated with osteoclast inhibitors (OIs).. *Journal of Clinical Oncology*, **2020**, 38, e19314-e19314	2.2	
204	Development and validation of natural language processing (NLP) algorithm for detection of distant versus local breast cancer recurrence and metastatic site.. *Journal of Clinical Oncology*, **2020**, 38, 2043-2043	2.2	1
203	Decision Making About Genetic Testing Among Women With a Personal and Family History of Breast Cancer. *JCO Oncology Practice*, **2020**, 16, e37-e55	2.3	7
202	Magnitude of reduction in risk of second contralateral breast cancer with bilateral mastectomy in patients with breast cancer: Data from California, 1998 through 2015. *Cancer*, **2020**, 126, 958-970	6.4	7
201	European polygenic risk score for prediction of breast cancer shows similar performance in Asian women. *Nature Communications*, **2020**, 11, 3833	17.4	31
200	Association of a Polygenic Risk Score With Breast Cancer Among Women Carriers of High- and Moderate-Risk Breast Cancer Genes. *JAMA Network Open*, **2020**, 3, e208501	10.4	38
199	Pathogenic Variants in Breast Cancer Susceptibility Genes in Older Women-Reply. *JAMA - Journal of the American Medical Association*, **2020**, 324, 397-398	27.4	
198	Breast Cancer Polygenic Risk Score and Contralateral Breast Cancer Risk. *American Journal of Human Genetics*, **2020**, 107, 837-848	11	12
197	Re-evaluating genetic variants identified in candidate gene studies of breast cancer risk using data from nearly 280,000 women of Asian and European ancestry. *EBioMedicine*, **2019**, 48, 203-211	8.8	9
196	Simulation Modeling to Extend Clinical Trials of Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Early Breast Cancer. *JNCI Cancer Spectrum*, **2019**, 3, pkz062	4.6	2
195	Primary care provider-reported involvement in breast cancer treatment decisions. *Cancer*, **2019**, 125, 1815-1822	6.4	8
194	Response to Peshkin, Isaacs, and Schwartz. *Journal of the National Cancer Institute*, **2019**, 111, 874	9.7	
193	Genetic Testing and Results in a Population-Based Cohort of Breast Cancer Patients and Ovarian Cancer Patients. *Journal of Clinical Oncology*, **2019**, 37, 1305-1315	2.2	126
192	Genomic landscape of ductal carcinoma in situ and association with progression. *Breast Cancer Research and Treatment*, **2019**, 178, 307-316	4.4	8

191	Chromatin Remodeling in Response to BRCA2-Crisis. *Cell Reports*, **2019**, 28, 2182-2193.e6	10.6 · 1
190	Multicenter Prospective Cohort Study of the Diagnostic Yield and Patient Experience of Multiplex Gene Panel Testing For Hereditary Cancer Risk. *JCO Precision Oncology*, **2019**, 3,	3.6 · 7
189	Patient-clinician interactions and disparities in breast cancer care: the equality in breast cancer care study. *Journal of Cancer Survivorship*, **2019**, 13, 968-980	5.1 · 8
188	Using natural language processing to construct a metastatic breast cancer cohort from linked cancer registry and electronic medical records data. *JAMIA Open*, **2019**, 2, 528-537	2.9 · 14
187	Preventive surgery after multiplex genetic panel testing (MGPT).. *Journal of Clinical Oncology*, **2019**, 37, 1525-1525	2.2 · 1
186	Breast cancer treatment according to pathogenic variants in cancer susceptibility genes in a population-based cohort.. *Journal of Clinical Oncology*, **2019**, 37, 560-560	2.2 · 2
185	Oncotype DX DCIS use and clinical utility: A SEER population-based study.. *Journal of Clinical Oncology*, **2019**, 37, e12046-e12046	2.2 · 1
184	Uptake of the 21-Gene Assay Among Women With Node-Positive, Hormone Receptor-Positive Breast Cancer. *Journal of the National Comprehensive Cancer Network: JNCCN*, **2019**, 17, 662-668	7.3 · 7
183	Prevalence and penetrance of breast cancer-associated mutations identified by multiple-gene sequencing in the Womens Health Initiative.. *Journal of Clinical Oncology*, **2019**, 37, 1513-1513	2.2
182	Radiomics features to identify distinct subtypes of triple-negative breast cancers.. *Journal of Clinical Oncology*, **2019**, 37, 3069-3069	2.2
181	Use, attitudes, and perceptions of tumor genomic testing: Survey of TAPUR physicians.. *Journal of Clinical Oncology*, **2019**, 37, 6531-6531	2.2 · 0
180	Differences among Asian/Asian American, and Caucasian breast and gynecologic cancer patient-reported survivorship needs, symptoms, and illness mindsets (N=220).. *Journal of Clinical Oncology*, **2019**, 37, 11620-11620	2.2
179	Adherence to breast cancer treatment guidelines according to pathogenic variants in cancer susceptibility genes in a population-based cohort.. *Journal of Clinical Oncology*, **2019**, 37, 34-34	2.2
178	Automatic inference of BI-RADS final assessment categories from narrative mammography report findings. *Journal of Biomedical Informatics*, **2019**, 92, 103137	10.2 · 6
177	Comparative effectiveness of first-line nab-paclitaxel versus paclitaxel monotherapy in triple-negative breast cancer. *Journal of Comparative Effectiveness Research*, **2019**, 8, 1173-1185	2.1 · 2
176	Natural Language Processing Approaches to Detect the Timeline of Metastatic Recurrence of Breast Cancer. *JCO Clinical Cancer Informatics*, **2019**, 3, 1-12	5.2 · 21
175	Guidelines Do Not Proscribe Surgeons Performing Genetic Testing-Reply. *JAMA Surgery*, **2019**, 154, 269-270	34
174	Distribution of global health measures from routinely collected PROMIS surveys in patients with breast cancer or prostate cancer. *Cancer*, **2019**, 125, 943-951	6.4 · 8

173	Cascade Genetic Testing of Relatives for Hereditary Cancer Risk: Results of an Online Initiative. *Journal of the National Cancer Institute*, **2019**, 111, 95-98	9.7	47
172	Patient Experiences and Clinician Views on the Role of Radiation Therapy for Ductal Carcinoma In Situ. *International Journal of Radiation Oncology Biology Physics*, **2018**, 100, 1237-1245	4	8
171	Association of Screening and Treatment With Breast Cancer Mortality by Molecular Subtype in US Women, 2000-2012. *JAMA - Journal of the American Medical Association*, **2018**, 319, 154-164	27.4	130
170	Recent Trends in Chemotherapy Use and Oncologists' Treatment Recommendations for Early-Stage Breast Cancer. *Journal of the National Cancer Institute*, **2018**, 110, 493-500	9.7	38
169	Intratumoral Spatial Heterogeneity at Perfusion MR Imaging Predicts Recurrence-free Survival in Locally Advanced Breast Cancer Treated with Neoadjuvant Chemotherapy. *Radiology*, **2018**, 288, 26-35	20.5	63
168	Common Model Inputs Used in CISNET Collaborative Breast Cancer Modeling. *Medical Decision Making*, **2018**, 38, 9S-23S	2.5	29
167	Differences in Breast Cancer Survival by Molecular Subtypes in the United States. *Cancer Epidemiology Biomarkers and Prevention*, **2018**, 27, 619-626	4	164
166	Higher Absolute Lymphocyte Counts Predict Lower Mortality from Early-Stage Triple-Negative Breast Cancer. *Clinical Cancer Research*, **2018**, 24, 2851-2858	12.9	38
165	What Factors Influence Women's Perceptions of their Systemic Recurrence Risk after Breast Cancer Treatment?. *Medical Decision Making*, **2018**, 38, 95-106	2.5	6
164	Unmet need for clinician engagement regarding financial toxicity after diagnosis of breast cancer. *Cancer*, **2018**, 124, 3668-3676	6.4	59
163	From the Past to the Present: Insurer Coverage Frameworks for Next-Generation Tumor Sequencing. *Value in Health*, **2018**, 21, 1062-1068	3.3	12
162	Rising rates of bilateral mastectomy with reconstruction following neoadjuvant chemotherapy. *International Journal of Cancer*, **2018**, 143, 3262-3272	7.5	9
161	Measuring serum melatonin in postmenopausal women: Implications for epidemiologic studies and breast cancer studies. *PLoS ONE*, **2018**, 13, e0195666	3.7	4
160	Uptake, Results, and Outcomes of Germline Multiple-Gene Sequencing After Diagnosis of Breast Cancer. *JAMA Oncology*, **2018**, 4, 1066-1072	13.4	87
159	Macrophages Promote Circulating Tumor Cell-Mediated Local Recurrence following Radiotherapy in Immunosuppressed Patients. *Cancer Research*, **2018**, 78, 4241-4252	10.1	24
158	Unmet need for clinician engagement about financial toxicity after diagnosis of breast cancer.. *Journal of Clinical Oncology*, **2018**, 36, 10080-10080	2.2	1
157	Computing the cost of care per day of breast cancer survivor care.. *Journal of Clinical Oncology*, **2018**, 36, 10-10	2.2	1
156	Promoting colorectal cancer (CRC) screening after multiplex genetic testing and genetic counseling.. *Journal of Clinical Oncology*, **2018**, 36, 1582-1582	2.2	

155	Genetic testing and results in population-based breast cancer patients and ovarian cancer patients.. *Journal of Clinical Oncology*, **2018**, 36, 1578-1578	2.2	
154	Promoting breast cancer screening after multiplex genetic panel testing (MGPT) and genetic counseling.. *Journal of Clinical Oncology*, **2018**, 36, 1581-1581	2.2	
153	Racial/ethnic differences in multiple-gene sequencing results for hereditary cancer risk. *Genetics in Medicine*, **2018**, 20, 234-239	8.1	72
152	Association of Germline Genetic Test Type and Results With Patient Cancer Worry After Diagnosis of Breast Cancer. *JCO Precision Oncology*, **2018**, 2018,	3.6	4
151	Gaps in Receipt of Clinically Indicated Genetic Counseling After Diagnosis of Breast Cancer. *Journal of Clinical Oncology*, **2018**, 36, 1218-1224	2.2	43
150	Rapid detection of recurrent mutations in Chinese breast and ovarian cancer patients with multiplex SNaPshot genotyping panels. *Oncotarget*, **2018**, 9, 7832-7843	3.3	6
149	Pathogenic Variants in Less Familiar Cancer Susceptibility Genes: What Happens After Genetic Testing?. *JCO Precision Oncology*, **2018**, 2, 1-10	3.6	2
148	Change in Survival in Metastatic Breast Cancer with Treatment Advances: Meta-Analysis and Systematic Review. *JNCI Cancer Spectrum*, **2018**, 2, pky062	4.6	102
147	Cancer Risk Estimates for Study of Multiple-Gene Testing After Diagnosis of Breast Cancer-Reply. *JAMA Oncology*, **2018**, 4, 1788	13.4	1
146	Patient communication of cancer genetic test results in a diverse population. *Translational Behavioral Medicine*, **2018**, 8, 85-94	3.2	21
145	Knowledge regarding and patterns of genetic testing in patients newly diagnosed with breast cancer participating in the iCanDecide trial. *Cancer*, **2018**, 124, 4000-4009	6.4	3
144	Can We Use Survival Data from Cancer Registries to Learn about Disease Recurrence? The Case of Breast Cancer. *Cancer Epidemiology Biomarkers and Prevention*, **2018**, 27, 1332-1341	4	17
143	Association of Attending Surgeon With Variation in the Receipt of Genetic Testing After Diagnosis of Breast Cancer. *JAMA Surgery*, **2018**, 153, 909-916	5.4	17
142	The impact of doctor-patient communication on patients' perceptions of their risk of breast cancer recurrence. *Breast Cancer Research and Treatment*, **2017**, 161, 525-535	4.4	23
141	Tumor Reversion Mutation Arising during Neoadjuvant Platinum-Based Chemotherapy in Triple-Negative Breast Cancer Is Associated with Therapy Resistance. *Clinical Cancer Research*, **2017**, 23, 3365-3370	12.9	39
140	Unsupervised Clustering of Quantitative Image Phenotypes Reveals Breast Cancer Subtypes with Distinct Prognoses and Molecular Pathways. *Clinical Cancer Research*, **2017**, 23, 3334-3342	12.9	54
139	Treatment-associated toxicities reported by patients with early-stage invasive breast cancer. *Cancer*, **2017**, 123, 1925-1934	6.4	34
138	Dynamic strategy for personalized medicine: An application to metastatic breast cancer. *Journal of Biomedical Informatics*, **2017**, 68, 50-57	10.2	9

137 — Genetic Testing and Counseling Among Patients With Newly Diagnosed Breast Cancer. *JAMA - Journal of the American Medical Association*, **2017**, 317, 531-534 — 27.4 — 78

136 — NCCN Guidelines Insights: Genetic/Familial High-Risk Assessment: Breast and Ovarian, Version 2.2017. *Journal of the National Comprehensive Cancer Network: JNCCN*, **2017**, 15, 9-20 — 7.3 — 319

135 — The Changing Landscape of Genetic Testing for Inherited Breast Cancer Predisposition. *Current Treatment Options in Oncology*, **2017**, 18, 27 — 5.4 — 21

134 — Trends in Reoperation After Initial Lumpectomy for Breast Cancer: Addressing Overtreatment in Surgical Management. *JAMA Oncology*, **2017**, 3, 1352-1357 — 13.4 — 79

133 — Payer Coverage for Hereditary Cancer Panels: Barriers, Opportunities, and Implications for the Precision Medicine Initiative. *Journal of the National Comprehensive Cancer Network: JNCCN*, **2017**, 15, 219-228 — 7.3 — 27

132 — Reply to Comment on 'Statin use and all-cancer survival: prospective results from the Women's Health Initiative'. *British Journal of Cancer*, **2017**, 116, e2 — 8.7 — 1

131 — Recurrence risk perception and quality of life following treatment of breast cancer. *Breast Cancer Research and Treatment*, **2017**, 161, 557-565 — 4.4 — 35

130 — The influence of 21-gene recurrence score assay on chemotherapy use in a population-based sample of breast cancer patients. *Breast Cancer Research and Treatment*, **2017**, 161, 587-595 — 4.4 — 8

129 — Second Opinions From Medical Oncologists for Early-Stage Breast Cancer: Prevalence, Correlates, and Consequences. *JAMA Oncology*, **2017**, 3, 391-397 — 13.4 — 17

128 — Contralateral Prophylactic Mastectomy Decisions in a Population-Based Sample of Patients With Early-Stage Breast Cancer. *JAMA Surgery*, **2017**, 152, 274-282 — 5.4 — 84

127 — Synergistic drug combinations from electronic health records and gene expression. *Journal of the American Medical Informatics Association: JAMIA*, **2017**, 24, 565-576 — 8.6 — 2

126 — Treatment decisions and employment of breast cancer patients: Results of a population-based survey. *Cancer*, **2017**, 123, 4791-4799 — 6.4 — 39

125 — Gaps in Incorporating Germline Genetic Testing Into Treatment Decision-Making for Early-Stage Breast Cancer. *Journal of Clinical Oncology*, **2017**, 35, 2232-2239 — 2.2 — 150

124 — Breast and Ovarian Cancer Penetrance Estimates Derived From Germline Multiple-Gene Sequencing Results in Women.. *JCO Precision Oncology*, **2017**, 1, 1-12 — 3.6 — 45

123 — Regional Variability in Percentage of Breast Cancers Reported as Positive for HER2 in California: Implications of Patient Demographics on Laboratory Benchmarks. *American Journal of Clinical Pathology*, **2017**, 148, 199-207 — 1.9 — 8

122 — Heterogeneous Enhancement Patterns of Tumor-adjacent Parenchyma at MR Imaging Are Associated with Dysregulated Signaling Pathways and Poor Survival in Breast Cancer. *Radiology*, **2017**, 285, 401-413 — 20.5 — 59

121 — Rising Bilateral Mastectomy Rates Among Neoadjuvant Chemotherapy Recipients in California From 1998 to 2012. *Annals of Surgery*, **2017**, 266, 353-360 — 7.8 — 9

120 — Oncologists' influence on receipt of adjuvant chemotherapy: does it matter whom you see for treatment of curable breast cancer?. *Breast Cancer Research and Treatment*, **2017**, 165, 751-756 — 4.4 — 7

119	Chemotherapy decisions and patient experience with the recurrence score assay for early-stage breast cancer. *Cancer*, **2017**, 123, 43-51	6.4	16
118	Pathogenic germline mutations in emerging cancer genes: What happens after panel testing?. *Journal of Clinical Oncology*, **2017**, 35, 1528-1528	2.2	1
117	Gaps in integrating genetic testing into management of breast cancer.. *Journal of Clinical Oncology*, **2017**, 35, 160-160	2.2	1
116	Recent time trends in chemotherapy use and oncologists' chemotherapy recommendations for early-stage, hormone receptor-positive breast cancer.. *Journal of Clinical Oncology*, **2017**, 35, 541-541	2.2	
115	Factors associated with 21-gene assay receipt among women with lymph node positive breast cancer.. *Journal of Clinical Oncology*, **2017**, 35, 6554-6554	2.2	
114	Treatment decisions and employment of breast cancer patients: Results of a population-based survey.. *Journal of Clinical Oncology*, **2017**, 35, 10052-10052	2.2	
113	Expanded yield of multiplex panel testing in fully accrued prospective trial.. *Journal of Clinical Oncology*, **2017**, 35, 1525-1525	2.2	
112	Performance of mutation risk prediction models in a racially diverse multi-gene panel testing cohort.. *Journal of Clinical Oncology*, **2017**, 35, 1523-1523	2.2	
111	Safety of multiplex gene testing for inherited cancer risk in a fully accrued prospective trial.. *Journal of Clinical Oncology*, **2017**, 35, 1576-1576	2.2	
110	Comprehensive spectrum of BRCA1 and BRCA2 deleterious mutations in breast cancer in Asian countries. *Journal of Medical Genetics*, **2016**, 53, 15-23	5.8	57
109	Occurrence and outcome of de novo metastatic breast cancer by subtype in a large, diverse population. *Cancer Causes and Control*, **2016**, 27, 1127-38	2.8	34
108	Protective Effects of Statins in Cancer: Should They Be Prescribed for High-Risk Patients?. *Current Atherosclerosis Reports*, **2016**, 18, 72	6	11
107	Statin use and all-cancer survival: prospective results from the Women's Health Initiative. *British Journal of Cancer*, **2016**, 115, 129-35	8.7	64
106	Safety of multiplex gene testing for inherited cancer risk: Interim analysis of a clinical trial.. *Journal of Clinical Oncology*, **2016**, 34, 1503-1503	2.2	1
105	Association of ovarian cancer (OC) risk with mutations detected by multiple-gene germline sequencing in 95,561 women.. *Journal of Clinical Oncology*, **2016**, 34, 5510-5510	2.2	1
104	Refining Breast Cancer Risk Stratification: Additional Genes, Additional Information. *American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting*, **2016**, 36, 44-56	7.1	12
103	Prevalence and predictors of second opinions from medical oncologists for early-stage breast cancer: Results from the iCanCare study.. *Journal of Clinical Oncology*, **2016**, 34, 185-185	2.2	
102	Recurrence risk perception and quality of life after treatment of breast cancer.. *Journal of Clinical Oncology*, **2016**, 34, 175-175	2.2	

101	Contralateral prophylactic mastectomy decision-making in the population-based iCanCare study of early-stage breast cancer patients.. *Journal of Clinical Oncology*, **2016**, 34, 177-177	2.2	
100	Breast oncology precision medicine: Genomic testing and treatment at the population level.. *Journal of Clinical Oncology*, **2016**, 34, 288-288	2.2	
99	Higher peripheral lymphocyte count to predict survival in triple-negative breast cancer (TNBC).. *Journal of Clinical Oncology*, **2016**, 34, 1010-1010	2.2	
98	Compliance with guidelines and factors associated with ordering the 21-gene breast cancer assay.. *Journal of Clinical Oncology*, **2016**, 34, 6552-6552	2.2	
97	Relationship between rising bilateral mastectomy rates and increased use of neoadjuvant chemotherapy (NAC) in California, 1998-2012.. *Journal of Clinical Oncology*, **2016**, 34, 1052-1052	2.2	
96	Clinical use of the 21-gene assay and patient experiences in early-stage breast cancer.. *Journal of Clinical Oncology*, **2016**, 34, 6501-6501	2.2	
95	Yield of multiplex panel testing compared to expert opinion and validated prediction models.. *Journal of Clinical Oncology*, **2016**, 34, 1509-1509	2.2	
94	Magnitude of invasive breast cancer (BC) risk associated with mutations detected by multiple-gene germline sequencing in 95,561 women.. *Journal of Clinical Oncology*, **2016**, 34, 1512-1512	2.2	
93	Dissemination of 21-gene assay testing among female breast cancer patients in the US.. *Journal of Clinical Oncology*, **2016**, 34, 6553-6553	2.2	
92	Refining Breast Cancer Risk Stratification: Additional Genes, Additional Information. *American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting*, **2016**, 35, 44-56	7.1	15
91	Addressing inherited predisposition for breast cancer in transplant recipients. *Journal of Surgical Oncology*, **2016**, 113, 605-8	2.8	0
90	Genetic/Familial High-Risk Assessment: Breast and Ovarian, Version 2.2015. *Journal of the National Comprehensive Cancer Network: JNCCN*, **2016**, 14, 153-62	7.3	123
89	Use of Gene Expression Profiling and Chemotherapy in Early-Stage Breast Cancer: A Study of Linked Electronic Medical Records, Cancer Registry Data, and Genomic Data Across Two Health Care Systems. *Journal of Oncology Practice*, **2016**, 12, e697-709	3.1	10
88	The Effect of Patient and Contextual Characteristics on Racial/Ethnic Disparity in Breast Cancer Mortality. *Cancer Epidemiology Biomarkers and Prevention*, **2016**, 25, 1064-72	4	19
87	Validation of self-reported comorbidity status of breast cancer patients with medical records: the California Breast Cancer Survivorship Consortium (CBCSC). *Cancer Causes and Control*, **2016**, 27, 391-401	2.8	12
86	Genetics of triple-negative breast cancer: Implications for patient care. *Current Problems in Cancer*, **2016**, 40, 130-140	2.3	17
85	Equivalent survival after nipple-sparing compared to non-nipple-sparing mastectomy: data from California, 1988-2013. *Breast Cancer Research and Treatment*, **2016**, 160, 333-338	4.4	2
84	A Systematic Comparison of Traditional and Multigene Panel Testing for Hereditary Breast and Ovarian Cancer Genes in More Than 1000 Patients. *Journal of Molecular Diagnostics*, **2015**, 17, 533-44	5.1	133

83	Navigating choices when applying multiple imputation in the presence of multi-level categorical interaction effects. *Statistical Methodology*, **2015**, 27, 82-99		3
82	Intersection of Race/Ethnicity and Socioeconomic Status in Mortality After Breast Cancer. *Journal of Community Health*, **2015**, 40, 1287-99	4	40
81	Treatment Decision Making and Genetic Testing for Breast Cancer: Mainstreaming Mutations. *JAMA - Journal of the American Medical Association*, **2015**, 314, 997-8	27.4	24
80	History of Recreational Physical Activity and Survival After Breast Cancer: The California Breast Cancer Survivorship Consortium. *American Journal of Epidemiology*, **2015**, 181, 944-55	3.8	15
79	Multigene Panel Testing in Oncology Practice: How Should We Respond?. *JAMA Oncology*, **2015**, 1, 277-8	13.4	53
78	Concerns about cancer risk and experiences with genetic testing in a diverse population of patients with breast cancer. *Journal of Clinical Oncology*, **2015**, 33, 1584-91	2.2	66
77	Diabetes and other comorbidities in breast cancer survival by race/ethnicity: the California Breast Cancer Survivorship Consortium (CBCSC). *Cancer Epidemiology Biomarkers and Prevention*, **2015**, 24, 361-8	4	53
76	How can we best respect patient autonomy in breast cancer treatment decisions?. *Breast Cancer Management*, **2015**, 4, 53-64	0.7	19
75	Phase II Study of Gemcitabine, Carboplatin, and Iniparib As Neoadjuvant Therapy for Triple-Negative and BRCA1/2 Mutation-Associated Breast Cancer With Assessment of a Tumor-Based Measure of Genomic Instability: PrECOG 0105. *Journal of Clinical Oncology*, **2015**, 33, 1895-901	2.2	166
74	Clinical Actionability of Multigene Panel Testing for Hereditary Breast and Ovarian Cancer Risk Assessment. *JAMA Oncology*, **2015**, 1, 943-51	13.4	226
73	Precision Medicine in Breast Cancer Care: An Early Glimpse of Impact. *JAMA Oncology*, **2015**, 1, 1109-10	13.4	5
72	Contribution of the neighborhood environment and obesity to breast cancer survival: the California Breast Cancer Survivorship Consortium. *Cancer Epidemiology Biomarkers and Prevention*, **2015**, 24, 1282-90	4	25
71	Linking electronic health records to better understand breast cancer patient pathways within and between two health systems. *EGEMS (Washington, DC)*, **2015**, 3, 1127	2.2	20
70	Breast Cancer Risk Reduction, Version 2.2015. *Journal of the National Comprehensive Cancer Network: JNCCN*, **2015**, 13, 880-915	7.3	39
69	Chromosomal copy number alterations for associations of ductal carcinoma in situ with invasive breast cancer. *Breast Cancer Research*, **2015**, 17, 108	8.3	15
68	Racial/ethnic and socioeconomic differences in short-term breast cancer survival among women in an integrated health system. *American Journal of Public Health*, **2015**, 105, 938-46	5.1	37
67	Next-generation sequencing for hereditary breast and gynecologic cancer risk assessment. *Current Opinion in Obstetrics and Gynecology*, **2015**, 27, 23-33	2.4	28
66	Multiple-Gene Panels and the Future of Genetic Testing. *Current Breast Cancer Reports*, **2015**, 7, 98-104	0.8	1

65	Breast Cancer Mortality in African-American and Non-Hispanic White Women by Molecular Subtype and Stage at Diagnosis: A Population-Based Study. *Cancer Epidemiology Biomarkers and Prevention*, **2015**, 24, 1039-45	4	73
64	Reply to S.M. Sorscher and A.B. Hafeez Bhatti. *Journal of Clinical Oncology*, **2015**, 33, 4233	2.2	
63	Lymphopenia after adjuvant radiotherapy (RT) to predict poor survival in triple-negative breast cancer (TNBC).. *Journal of Clinical Oncology*, **2015**, 33, 1069-1069	2.2	9
62	Clinical impact of multi-gene panel testing for hereditary breast and ovarian cancer risk assessment.. *Journal of Clinical Oncology*, **2015**, 33, 1513-1513	2.2	1
61	Genetic testing decisions of breast cancer patients: Results from the iCanCare study.. *Journal of Clinical Oncology*, **2015**, 33, 1541-1541	2.2	1
60	Statin use and all-cancer mortality: Prospective results from the Women Health Initiative.. *Journal of Clinical Oncology*, **2015**, 33, 1506-1506	2.2	2
59	Addressing lack of US insurance coverage of Cancer Hereditary Multiplex Testing (CHMT).. *Journal of Clinical Oncology*, **2015**, 33, e17515-e17515	2.2	
58	Contralateral prophylactic mastectomy decision-making in the population-based iCanCare study of early-stage breast cancer patients: Knowledge and physician influence.. *Journal of Clinical Oncology*, **2015**, 33, 1011-1011	2.2	
57	Prevalence and consequences of second opinions from medical oncologists for early-stage breast cancer: Results from the iCanCare study.. *Journal of Clinical Oncology*, **2015**, 33, 6508-6508	2.2	
56	Beyond barriers: fundamental 'disconnects' underlying the treatment of breast cancer patients' sexual health. *Culture, Health and Sexuality*, **2014**, 16, 1169-80	2.5	17
55	Clinical evaluation of a multiple-gene sequencing panel for hereditary cancer risk assessment. *Journal of Clinical Oncology*, **2014**, 32, 2001-9	2.2	363
54	Genetic/familial high-risk assessment: breast and ovarian, version 1.2014. *Journal of the National Comprehensive Cancer Network: JNCCN*, **2014**, 12, 1326-38	7.3	101
53	Breast cancer treatment across health care systems: linking electronic medical records and state registry data to enable outcomes research. *Cancer*, **2014**, 120, 103-11	6.4	39
52	Use of and mortality after bilateral mastectomy compared with other surgical treatments for breast cancer in California, 1998-2011. *JAMA - Journal of the American Medical Association*, **2014**, 312, 902-14	27.4	178
51	Obesity and mortality after breast cancer by race/ethnicity: The California Breast Cancer Survivorship Consortium. *American Journal of Epidemiology*, **2014**, 179, 95-111	3.8	75
50	Use of the 21-gene recurrence score assay (RS) and chemotherapy (CT) across health care (HC) systems.. *Journal of Clinical Oncology*, **2014**, 32, 6580-6580	2.2	
49	Chromosomal copy number alterations (CNAs) for risk assessment of ductal carcinoma in situ (DCIS).. *Journal of Clinical Oncology*, **2014**, 32, 565-565	2.2	
48	The California Breast Cancer Survivorship Consortium (CBCSC): prognostic factors associated with racial/ethnic differences in breast cancer survival. *Cancer Causes and Control*, **2013**, 24, 1821-36	2.8	41

#	Reference	IF	Citations
47	A clinical trial of lovastatin for modification of biomarkers associated with breast cancer risk. *Breast Cancer Research and Treatment*, **2013**, 142, 389-98	4.4	24
46	The California breast density information group: a collaborative response to the issues of breast density, breast cancer risk, and breast density notification legislation. *Radiology*, **2013**, 269, 887-92	20.5	80
45	Patterns and predictors of breast cancer chemotherapy use in Kaiser Permanente Northern California, 2004-2007. *Breast Cancer Research and Treatment*, **2013**, 137, 247-60	4.4	32
44	Feasibility evaluation of an online tool to guide decisions for BRCA1/2 mutation carriers. *Familial Cancer*, **2013**, 12, 65-73	3	8
43	Information technology interventions to improve cancer care quality: a report from the American Society of Clinical Oncology Quality Care Symposium. *Journal of Oncology Practice*, **2013**, 9, 142-4	3.1	5
42	A Population-Based Observational Study of First-Course Treatment and Survival for Adolescent and Young Adult Females with Breast Cancer. *Journal of Adolescent and Young Adult Oncology*, **2013**, 2, 95-103	2.2	14
41	A young woman with bilateral breast cancer: identifying a genetic cause and implications for management. *Journal of the National Comprehensive Cancer Network: JNCCN*, **2013**, 11, 512-7	7.3	2
40	A simulation model to predict the impact of prophylactic surgery and screening on the life expectancy of BRCA1 and BRCA2 mutation carriers. *Cancer Epidemiology Biomarkers and Prevention*, **2012**, 21, 1066-77	4	37
39	Online tool to guide decisions for BRCA1/2 mutation carriers. *Journal of Clinical Oncology*, **2012**, 30, 497-506	25	69
38	Occurrence of breast cancer subtypes in adolescent and young adult women. *Breast Cancer Research*, **2012**, 14, R55	8.3	134
37	Novel BRCA1 and BRCA2 genomic rearrangements in Southern Chinese breast/ovarian cancer patients. *Breast Cancer Research and Treatment*, **2012**, 136, 931-3	4.4	13
36	Breast cancer risk factors differ between Asian and white women with BRCA1/2 mutations. *Familial Cancer*, **2012**, 11, 429-39	3	21
35	Genetic Polymorphisms as Predictors of Breast Cancer Risk. *Current Breast Cancer Reports*, **2012**, 4, 232-239	2.3	1
34	Single cell profiling of circulating tumor cells: transcriptional heterogeneity and diversity from breast cancer cell lines. *PLoS ONE*, **2012**, 7, e33788	3.7	415
33	Accuracy of BRCA1/2 mutation prediction models for different ethnicities and genders: experience in a southern Chinese cohort. *World Journal of Surgery*, **2012**, 36, 702-13	3.3	17
32	Identification of BRCA1/2 founder mutations in Southern Chinese breast cancer patients using gene sequencing and high resolution DNA melting analysis. *PLoS ONE*, **2012**, 7, e43994	3.7	74
31	Patient, hospital, and neighborhood factors associated with treatment of early-stage breast cancer among Asian American women in California. *Cancer Epidemiology Biomarkers and Prevention*, **2012**, 21, 821-34	4	11
30	Age-specific incidence of breast cancer subtypes: understanding the black-white crossover. *Journal of the National Cancer Institute*, **2012**, 104, 1094-101	9.7	157

29	Reply to D.G. Evans et al. *Journal of Clinical Oncology*, **2012**, 30, 1143-1144	2.2	1
28	Oncoshare: lessons learned from building an integrated multi-institutional database for comparative effectiveness research **2012**, 2012, 970-8	0.7	18
27	A prospective study of total gastrectomy for CDH1-positive hereditary diffuse gastric cancer. *Annals of Surgical Oncology*, **2011**, 18, 2594-8	3.1	73
26	Asian ethnicity and breast cancer subtypes: a study from the California Cancer Registry. *Breast Cancer Research and Treatment*, **2011**, 127, 471-8	4.4	118
25	Breast cancer risk for noncarriers of family-specific BRCA1 and BRCA2 mutations: findings from the Breast Cancer Family Registry. *Journal of Clinical Oncology*, **2011**, 29, 4505-9	2.2	32
24	Survival analysis of cancer risk reduction strategies for BRCA1/2 mutation carriers. *Journal of Clinical Oncology*, **2010**, 28, 222-31	2.2	189
23	Increasing mastectomy rates for early-stage breast cancer? Population-based trends from California. *Journal of Clinical Oncology*, **2010**, 28, e155-7; author reply e158	2.2	48
22	Lifetime risks of specific breast cancer subtypes among women in four racial/ethnic groups. *Breast Cancer Research*, **2010**, 12, R99	8.3	117
21	BRCA1 and BRCA2 mutations across race and ethnicity: distribution and clinical implications. *Current Opinion in Obstetrics and Gynecology*, **2010**, 22, 72-8	2.4	129
20	Genetic/familial high-risk assessment: breast and ovarian. *Journal of the National Comprehensive Cancer Network: JNCCN*, **2010**, 8, 562-94	7.3	169
19	High-resolution melting analysis for rapid screening of BRCA2 founder mutations in Southern Chinese breast cancer patients. *Breast Cancer Research and Treatment*, **2010**, 122, 605-7	4.4	5
18	Identification and Management of Women at High Familial Risk for Breast Cancer **2010**, 135-145		
17	Second primary breast cancer occurrence according to hormone receptor status. *Journal of the National Cancer Institute*, **2009**, 101, 1058-65	9.7	90
16	Performance of prediction models for BRCA mutation carriage in three racial/ethnic groups: findings from the Northern California Breast Cancer Family Registry. *Cancer Epidemiology Biomarkers and Prevention*, **2009**, 18, 1084-91	4	53
15	The decline in breast cancer incidence: real or imaginary?. *Current Oncology Reports*, **2009**, 11, 21-8	6.3	15
14	Statins May Reduce Breast Cancer Risk, Particularly Hormone Receptor-Negative Disease. *Current Breast Cancer Reports*, **2009**, 1, 148-156	0.8	11
13	Magnetic resonance galactography: a feasibility study in women with prior atypical breast duct cytology. *Breast Journal*, **2008**, 14, 211-4	1.2	3
12	Performance of BRCA1/2 mutation prediction models in Asian Americans. *Journal of Clinical Oncology*, **2008**, 26, 4752-8	2.2	52

List of Publications

11	Cancer risk reduction and reproductive concerns in female BRCA1/2 mutation carriers. *Familial Cancer*, **2008**, 7, 179-86	3	54
10	A cost-effectiveness analysis of adjuvant trastuzumab regimens in early HER2/neu-positive breast cancer. *Journal of Clinical Oncology*, **2007**, 25, 634-41	2.2	100
9	Ductal pattern enhancement on magnetic resonance imaging of the breast due to ductal lavage. *Breast Journal*, **2007**, 13, 281-6	1.2	5
8	A carrier of both MEN1 and BRCA2 mutations: case report and review of the literature. *Cancer Genetics and Cytogenetics*, **2007**, 179, 89-92		10
7	CDH1 truncating mutations in the E-cadherin gene: an indication for total gastrectomy to treat hereditary diffuse gastric cancer. *Annals of Surgery*, **2007**, 245, 873-9	7.8	133
6	Cost-effectiveness of screening BRCA1/2 mutation carriers with breast magnetic resonance imaging. *JAMA - Journal of the American Medical Association*, **2006**, 295, 2374-84	27.4	201
5	Biomedical terahertz imaging with a quantum cascade laser. *Applied Physics Letters*, **2006**, 88, 153903	3.4	98
4	Opinions of women with high inherited breast cancer risk about prophylactic mastectomy: an initial evaluation from a screening trial including magnetic resonance imaging and ductal lavage. *Health Expectations*, **2005**, 8, 221-33	3.7	17
3	Histologic types of epithelial ovarian cancer: have they different risk factors?. *Gynecologic Oncology* , **2005**, 96, 520-30	4.9	132
2	Ductal lavage of fluid-yielding and non-fluid-yielding ducts in BRCA1 and BRCA2 mutation carriers and other women at high inherited breast cancer risk. *Cancer Epidemiology Biomarkers and Prevention*, **2005**, 14, 1082-9	4	20
1	Breast magnetic resonance image screening and ductal lavage in women at high genetic risk for breast carcinoma. *Cancer*, **2004**, 100, 479-89	6.4	70